Should Investors Brace for Bad News From Novavax's Looming Clinical Update?

One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a clinical study. All Novavax did was announce that a call would be held on Monday, July 24, to discuss results from a phase 2 study of its RSV F vaccine.

Based on the stock's surge, investors were obviously viewing the update as a positive development. Despite no mention whatsoever in Novavax's press release about how well its RSV F vaccine performed, many automatically assumed good news. But should investors brace themselves for bad news instead?

Image source: Getty Images.

Source: Fool.com